Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 1256Neoplasms 1074Carcinoma, Non-Small-Cell Lung 874Prostatic Neoplasms 714Lung Neoplasms 596Colorectal Neoplasms 590Neoplasm Metastasis 452Multiple Myeloma 432Leukemia, Myeloid, Acute 423Pancreatic Neoplasms 370Ovarian Neoplasms 367Melanoma 324Carcinoma, Hepatocellular 299Squamous Cell Carcinoma of Head and Neck 276Brain Neoplasms 275Recurrence 273Stomach Neoplasms 245Head and Neck Neoplasms 241Glioblastoma 239Carcinoma, Renal Cell 227Lymphoma 226Triple Negative Breast Neoplasms 225Precursor Cell Lymphoblastic Leukemia-Lymphoma 222Hematologic Neoplasms 212Urinary Bladder Neoplasms 211Uterine Cervical Neoplasms 200Endometrial Neoplasms 199Sarcoma 195Glioma 194Lymphoma, Non-Hodgkin 188

Interventions

pembrolizumab 1enfortumab vedotin 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Muscle-invasive Bladder Cancer × 90 days × Clear all
NCT07475806 2026-05-15

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

Astellas Pharma Inc

Phase 2 Recruiting
240 enrolled
Genitourinary

Muscle-invasive Bladder Cancer

NCT04660344 2026-03-27

IMvigor011

Hoffmann-La Roche

Phase 3 Active not recruiting
761 enrolled 1 FDA
Genitourinary

Muscle-invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡